

James A Russell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7891687/james-a-russell-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

8,604
citations

37
h-index

92
g-index

121
ext. papers

10,850
ext. citations

8.3
avg, IF

6.21
L-index

#	Paper	IF	Citations
97	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19.. <i>Journal of Proteome Research</i> , 2022 ,	5.6	4
96	Improving Bed Utilization in a Cohort of Bariatric Surgical Patients Using a Perioperative Obstructive Sleep Apnea Treatment and Bed Triage Protocol.. <i>Obesity Surgery</i> , 2022 , 1	3.7	
95	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study.. <i>CMAJ Open</i> , 2022 , 10, E379-E389	2.5	1
94	Virus Meets Host: SARS-CoV-2 Pathogenesis. <i>World Scientific Series in Global Healthcare Economics and Public Policy</i> , 2022 , 35-49	0.2	
93	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , 2021 , 3, 965-975	2	5
92	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. <i>Circulation</i> , 2021 , 143, 921-934	16.7	20
91	Vasopressor Therapy in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021 , 42, 59-77	3.9	5
90	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021 , 49, 1558-1566	1.4	10
89	Current practice and evolving concepts in septic shock resuscitation.. <i>Intensive Care Medicine</i> , 2021 , 48, 148	14.5	5
88	Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial 2020 , 2, e0104		1
87	How have genomics informed our understanding of critical illness? 2020 , 23-35.e1		
86	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. <i>BMJ Open</i> , 2020 , 10, e040768	3	3
85	Very Low Density Lipoprotein Receptor Sequesters Lipopolysaccharide Into Adipose Tissue During Sepsis. <i>Critical Care Medicine</i> , 2020 , 48, 41-48	1.4	9
84	The Specific Organism: Not Bacterial Gram Type: Drives the Inflammatory Response in Septic Shock. <i>Journal of Innate Immunity</i> , 2020 , 12, 182-190	6.9	0
83	Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1476-1485	27.4	54
82	Early May Be Better: Early Low-Dose Norepinephrine in Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1049-1051	10.2	5
81	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. <i>Intensive Care Medicine</i> , 2019 , 45, 844-855	14.5	36

80	Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients. <i>Scientific Reports</i> , 2019 , 9, 10588	4.9	11
79	Vasopressor therapy in critically ill patients with shock. <i>Intensive Care Medicine</i> , 2019 , 45, 1503-1517	14.5	30
78	Genetic Polymorphisms in Sepsis and Cardiovascular Disease: Do Similar Risk Genes Suggest Similar Drug Targets?. <i>Chest</i> , 2019 , 155, 1260-1271	5.3	15
77	Toward Increased Understanding of the Steroid Controversy in Septic Shock. <i>Critical Care Medicine</i> , 2019 , 47, 1677-1679	1.4	3
76	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 854-862	10.2	44
75	Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 250-257	4.7	24
74	Is Heparin-Binding Protein Inhibition a Mechanism of Albumin α Efficacy in Human Septic Shock?. <i>Critical Care Medicine</i> , 2018 , 46, e364-e374	1.4	10
73	Intensive care medicine in 2050: vasopressors in sepsis. <i>Intensive Care Medicine</i> , 2018 , 44, 1130-1132	14.5	4
72	Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. <i>Annals of Intensive Care</i> , 2018 , 8, 16	8.9	2
71	In Reply. <i>Anesthesiology</i> , 2018 , 128, 230-231	4.3	
70	A global perspective on vasoactive agents in shock. <i>Intensive Care Medicine</i> , 2018 , 44, 833-846	14.5	40
69	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. <i>Pregnancy Hypertension</i> , 2018 , 13, 121-126	2.6	3
68	Pathophysiology of Septic Shock. <i>Critical Care Clinics</i> , 2018 , 34, 43-61	4.5	49
67	CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. <i>Scientific Reports</i> , 2018 , 8, 16764	4.9	18
66	Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. <i>Journal of Intensive Care</i> , 2018 , 6, 73	7	7
65	The Understanding and Management of Organism Toxicity in Septic Shock. <i>Journal of Innate Immunity</i> , 2018 , 10, 502-514	6.9	10
64	Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. <i>Journal of Critical Care</i> , 2018 , 47, 333-337	4	18
63	Association between chronic exposure to air pollution and mortality in the acute respiratory distress syndrome. <i>Environmental Pollution</i> , 2017 , 224, 352-356	9.3	22

62	The intensive care medicine research agenda on septic shock. <i>Intensive Care Medicine</i> , 2017 , 43, 1294-1305	4.5	44
61	Heparin-Binding Protein (HBP): A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury. <i>Shock</i> , 2017 , 48, 313-320	3.4	30
60	The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience. <i>Critical Care Medicine</i> , 2017 , 45, 940-948	1.4	41
59	Selepressin, a novel selective vasopressin V agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. <i>Critical Care</i> , 2017 , 21, 213	10.8	62
58	Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Intensive Care Medicine</i> , 2017 , 43, 1751-1763	14.5	123
57	Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Critical Care Medicine</i> , 2017 , 45, 2078-2088	1.4	140
56	Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). <i>Intensive Care Medicine</i> , 2017 , 43, 1781-1792	14.5	77
55	Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). <i>Critical Care Medicine</i> , 2017 , 45, 2089-2098	1.4	31
54	Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2017 , 19, 43-49	2.8	10
53	Short-Term Organ Dysfunction Is Associated With Long-Term (10-Yr) Mortality of Septic Shock. <i>Critical Care Medicine</i> , 2016 , 44, e728-36	1.4	15
52	Vasopressors During Sepsis: Selection and Targets. <i>Clinics in Chest Medicine</i> , 2016 , 37, 251-62	5.3	10
51	Trials in adult critical care that show increased mortality of the new intervention: Inevitable or preventable mishaps?. <i>Annals of Intensive Care</i> , 2016 , 6, 17	8.9	1
50	Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. <i>PLoS ONE</i> , 2016 , 11, e0155030	3.7	63
49	Early Liberal Fluids for Sepsis Patients Are Harmful. <i>Critical Care Medicine</i> , 2016 , 44, 2258-2262	1.4	16
48	Elevated Plasma Angiopoietin-2 Levels Are Associated With Fluid Overload, Organ Dysfunction, and Mortality in Human Septic Shock. <i>Critical Care Medicine</i> , 2016 , 44, 2018-2027	1.4	37
47	Genomics and pharmacogenomics of sepsis: so close and yet so far. <i>Critical Care</i> , 2016 , 20, 185	10.8	11
46	Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. <i>Journal of Intensive Care</i> , 2016 , 4, 24	7	31
45	Plasma cytokine levels predict response to corticosteroids in septic shock. <i>Intensive Care Medicine</i> , 2016 , 42, 1970-1979	14.5	24

44	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. <i>Intensive Care Medicine</i> , 2016 , 42, 1958-1969	8.1	81
43	Hyperchloremia and moderate increase in serum chloride are associated with acute kidney injury in severe sepsis and septic shock patients. <i>Critical Care</i> , 2016 , 20, 315	10.8	86
42	Heparin-binding protein is important for vascular leak in sepsis. <i>Intensive Care Medicine Experimental</i> , 2016 , 4, 33	3.7	48
41	Advances in Sepsis Research. <i>Clinics in Chest Medicine</i> , 2015 , 36, 521-30	5.3	13
40	The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 1275-86	10.2	35
39	The meta-genome of sepsis: host genetics, pathogens and the acute immune response. <i>Journal of Innate Immunity</i> , 2014 , 6, 272-83	6.9	26
38	Prolonged QTc affects short-term and long-term outcomes in patients with normal left ventricular function undergoing cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 147, 1627-33	1.5	2
37	An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation. <i>EBioMedicine</i> , 2014 , 1, 64-71	8.8	84
36	Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. <i>Critical Care Medicine</i> , 2014 , 42, 1812-20	1.4	36
35	PCSK9 is a critical regulator of the innate immune response and septic shock outcome. <i>Science Translational Medicine</i> , 2014 , 6, 258ra143	17.5	213
34	Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 356-64	10.2	52
33	Noncanonical Nuclear Factor Kappa B (NF- κ B) Signaling and Potential for Therapeutics in Sepsis. <i>Current Infectious Disease Reports</i> , 2013 , 15, 364-71	3.9	4
32	Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. <i>Critical Care</i> , 2013 , 17, R117	10.8	31
31	Cytokines and signaling molecules predict clinical outcomes in sepsis. <i>PLoS ONE</i> , 2013 , 8, e79207	3.7	26
30	Potential for overuse of corticosteroids and vasopressin in septic shock. <i>Critical Care</i> , 2012 , 16, 447	10.8	5
29	Inotropes and vasopressors: more than haemodynamics!. <i>British Journal of Pharmacology</i> , 2012 , 165, 2009-11	8.6	16
28	The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. <i>Chest</i> , 2012 , 142, 593-605	5.3	58
27	Molecular mechanisms of sepsis. <i>Contributions To Microbiology</i> , 2011 , 17, 48-85		25

26	Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. <i>Critical Care Medicine</i> , 2011 , 39, 1641-8	1.4	35
25	Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. <i>Critical Care Medicine</i> , 2011 , 39, 259-65	1.4	979
24	Gene expression in human sepsis: what have we learned?. <i>Critical Care</i> , 2011 , 15, 121	10.8	9
23	A single nucleotide polymorphism in NF- κ B inducing kinase is associated with mortality in septic shock. <i>Journal of Immunology</i> , 2011 , 186, 2321-8	5.3	35
22	Leucyl/cystinyl aminopeptidase gene variants in septic shock. <i>Chest</i> , 2011 , 139, 1042-1049	5.3	45
21	Vasopressin and its immune effects in septic shock. <i>Journal of Innate Immunity</i> , 2010 , 2, 446-60	6.9	43
20	beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 143-9	10.2	63
19	The effects of vasopressin on acute kidney injury in septic shock. <i>Intensive Care Medicine</i> , 2010 , 36, 83-91	14.5	159
18	Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. <i>Critical Care Medicine</i> , 2009 , 37, 811-8	1.4	185
17	Vasopressin versus norepinephrine infusion in patients with septic shock. <i>New England Journal of Medicine</i> , 2008 , 358, 877-87	59.2	1340
16	Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 710-20	10.2	226
15	Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. <i>Human Genetics</i> , 2008 , 123, 661-3	6.3	43
14	Vasopressin in septic shock. <i>Critical Care Medicine</i> , 2007 , 35, S609-15	1.4	30
13	Vasopressin in vasodilatory and septic shock. <i>Current Opinion in Critical Care</i> , 2007 , 13, 383-91	3.5	50
12	Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. <i>Critical Care Medicine</i> , 2007 , 35, 12-7	1.4	55
11	Management of sepsis. <i>New England Journal of Medicine</i> , 2006 , 355, 1699-713	59.2	868
10	The association of interleukin 6 haplotype clades with mortality in critically ill adults. <i>Archives of Internal Medicine</i> , 2005 , 165, 75-82		83
9	Pharmacogenomics in sepsis and septic shock. <i>Drug Development Research</i> , 2005 , 64, 181-194	5.1	

8	Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. <i>Chest</i> , 2005 , 128, 1690-8	5.3	85
7	Albumin versus crystalloid for pump priming in cardiac surgery: meta-analysis of controlled trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2004 , 18, 429-37	2.1	83
6	Beneficial effects of short-term vasopressin infusion during severe septic shock. <i>Anesthesiology</i> , 2002 , 96, 576-82	4.3	502
5	The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. <i>Intensive Care Medicine</i> , 2001 , 27, 1416-21	14.5	331
4	Physiology of vasopressin relevant to management of septic shock. <i>Chest</i> , 2001 , 120, 989-1002	5.3	496
3	The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. <i>New England Journal of Medicine</i> , 1997 , 336, 912-8	59.2	679
2	Decreased left ventricular contractility during porcine endotoxemia is not prevented by ibuprofen. <i>Critical Care Medicine</i> , 1996 , 24, 815-9	1.4	18
1	Sustained Dysregulation of the Plasma Renin-angiotensin System in Acute COVID-19		3